Filed Pursuant to Rule 424(b)(3)
Registration No. 333-281768
Prospectus Supplement
(To the Prospectus dated
September 3, 2024)
9,666,183 Shares of Common Stock
This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated September 3, 2024 (the “Original
Prospectus”) of Biora Therapeutics, Inc. (the “Company”), relating to the offering on a resale basis of, among other securities, an aggregate of 301,886 shares of common stock, par value $0.001 per share (the “Common
Stock”), issuable upon the exercise of warrants to purchase up to an aggregate of 301,886 shares of Common Stock at an original exercise price of $11.00 per share (the “Existing Warrants”). The Existing Warrants have been amended as
described below under “Amendments to Existing Warrants.” All share and per share information included in this prospectus supplement has been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on October 18, 2024.
This prospectus supplement should be read in
conjunction with the Original Prospectus, and is qualified by reference to the Original Prospectus, except to the extent that the information presented herein supersedes the information contained in the Original Prospectus. This prospectus
supplement is not complete without, and may only be delivered or used in connection with, the Original Prospectus, including any amendments or supplements thereto. We may amend or supplement the Original Prospectus from time to time by filing
amendments or supplements as required. You should read the entire Original Prospectus and any amendments or supplements carefully before you make an investment decision.
Our Common Stock is listed on the Nasdaq Global Market under the symbol “BIOR.” On October 25, 2024, the last reported sale price of our Common
Stock on the Nasdaq Global Market was $3.90 per share.
Investing in
our securities involves a high degree of risk. See “Risk Factors” in the Original Prospectus and documents incorporated therein by reference for a discussion of such risk factors, which factors should be read carefully in connection with
an investment in our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of
these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.